Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Analysts at Wedbush reduced their FY2025 EPS estimates for Fennec Pharmaceuticals in a note issued to investors on Thursday, November 7th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $0.07 per share for the year, down from their previous estimate of $0.08. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $3.12 EPS.
Fennec Pharmaceuticals Trading Up 0.5 %
Shares of Fennec Pharmaceuticals stock opened at C$5.92 on Monday. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm has a fifty day moving average price of C$6.55 and a 200 day moving average price of C$8.27. Fennec Pharmaceuticals has a 1 year low of C$5.70 and a 1 year high of C$15.43. The stock has a market cap of C$161.97 million, a PE ratio of 59.20 and a beta of 0.25.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
- Five stocks we like better than Fennec Pharmaceuticals
- Insider Buying Explained: What Investors Need to Know
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Earnings Per Share Calculator: How to Calculate EPS
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.